GSK buys rights to Hansoh Pharma antibody-drug conjugate
Sharecast
Published Dec 20, 2023 14:07
Updated Dec 20, 2023 14:36
GSK buys rights to Hansoh Pharma antibody-drug conjugate
Sharecast - Under the terms of the deal, GSK will pay $185m upfront and Hansoh will be eligible to receive up to $1.525bn in success-based milestones for HS-20093.
The ADC utilises a clinically-validated topoisomerase inhibitor (TOPOi) payload. Under the agreement, GSK will obtain exclusive worldwide rights excluding China’s mainland, Hong Kong, Macau, and Taiwan to progress clinical development and commercialisation of HS-20093.
Upon commercialisation, the pharmaceutical giant will pay tiered royalties on global net sales outside of China’s mainland, Hong Kong, Macau, and Taiwan.
GSK (LON:GSK) said the deal provides it with a second clinical-stage ADC that "complements its existing capabilities and strengths in developing medicines to address unmet medical needs in various solid tumours".
HS-20093 is currently being investigated in ongoing phase I and II trials in China. Data from the ARTEMIS-001 phase I trial for HS-20093 in advanced solid tumours was presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting. Initial clinical activity was observed in small cell lung cancer, non-small cell lung cancer and sarcoma with multiple confirmed responses and a manageable safety profile.
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.